Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02965703 · ClinicalTrials.gov registry record · Phase 2
Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma
A Phase 2 study of Colorectal Carcinoma and Colorectal Adenoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT02965703: Active Phase 2 study of Colorectal Carcinoma and Colorectal Adenoma, sponsored by National Cancer Institute (NCI).
NCT02965703 is a Phase 2 study of Colorectal Carcinoma and Colorectal Adenoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 81 participants, below the 1,095-participant average among 53 other Colorectal Carcinoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02965703, a Phase 2 study of Colorectal Carcinoma and Colorectal Adenoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase IIa trial studies how well aspirin works in preventing colorectal cancer in patients with colorectal adenoma. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Change in the ratio of proliferation to apoptosis biomarkers (Ki67 density index: BAX density index, measured continuously after IHC staining) in colorectal mucosa of compliant participants
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Questionnaire Administration
- DRUG Aspirin
- OTHER Placebo Administration
- PROCEDURE Rectal Biopsy
Study Locations (1)
Tennessee
- Vanderbilt University/Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2018-01-16 |
| Est. Completion | 2026-12-24 |
| Phase | Phase 2 |
What the registry record for NCT02965703 still lists
NCT02965703 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 1,095-participant average among 53 other Colorectal Carcinoma trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Colorectal Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT02965703 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT02965703 about?
NCT02965703 is a clinical study titled "Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma". This phase IIa trial studies how well aspirin works in preventing colorectal cancer in patients with colorectal adenoma. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT02965703?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2018-01-16. Estimated completion is 2026-12-24.
What conditions does trial NCT02965703 study?
This clinical trial studies the following conditions: Colorectal Carcinoma, Colorectal Adenoma.
What interventions are being tested in trial NCT02965703?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Aspirin (DRUG), Placebo Administration (OTHER), Rectal Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02965703?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02965703 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02965703's enrollment target sits among peer trials
81 35th of 53 higher than 19 of 53 other Colorectal Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RECRUITING · Phase 2
-
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
ACTIVE NOT RECRUITING · Phase 2
-
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps
ACTIVE NOT RECRUITING · Phase 2
-
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI